Skip to Content

Bausch Health Companies Inc BHC

Rating as of

Morningstar’s Analysis

Valuation
Currency in CAD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Bausch Health Divestitures Accelerate Debt Paydown and Spin-Off Plans; Few Surprises in Q3 Earnings

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

While Bausch Health's third-quarter earnings did not provide much surprise, the company announced an acceleration of the Bausch and Lomb and Solta Medical spin-offs. We are maintaining our $26 fair value estimate (CAD 32) and no-moat rating, and there is no change to our long-term expectations. We intend to re-evaluate our valuation of Bausch Health once more details are disclosed on the upcoming spun businesses in early 2022.

Read Full Analysis

Company Profile

Business Description

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international (55% of revenue), Salix Pharmaceuticals (25%), ortho dermatology (6%), and diversified products (14%), and approximately 13% of revenue is attributable to non-U.S. markets. Bausch is the market leader in consumer visioncare in India and China and the fourth- largest visioncare company by sales in the United States.

Contact
2150 Saint Elzear Boulvard West
Laval, QC, H7L 4A8, Canada
T +1 514 744-6792
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 21,600